PMID- 18048068
OWN - NLM
STAT- MEDLINE
DCOM- 20080512
LR  - 20221207
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 54
IP  - 2
DP  - 2008 Feb
TI  - The differential regulation of BDNF and TrkB levels in juvenile rats after four 
      days of escitalopram and desipramine treatment.
PG  - 251-7
AB  - Major depressive disorder is a major health problem in adults and is now 
      recognized as a substantial problem in children as well. Tricyclic 
      antidepressants, including desipramine (DMI), are no better than placebo in 
      treating childhood and adolescent depression, but are effective in treating adult 
      depression. Several studies have suggested that normal BDNF (brain-derived 
      neurotrophic factor) signaling is necessary for antidepressant drug action. 
      Antidepressant drugs induce several plastic changes in the rodent brain which may 
      be associated with changes in BDNF levels and/or with BDNF function. In the 
      present study we report parallel measurements of BDNF mRNA and protein in the 
      frontal cortex and hippocampus after four days of twice daily treatments with 
      escitalopram, a selective serotonin reuptake inhibitor, and desipramine, a 
      tricyclic antidepressant. Post-natal day 13, 21, 28 and adult rats were used in 
      this study. TrkB (the primary receptor for BDNF) mRNA levels were also examined 
      under the same treatment conditions. BDNF mRNA and protein levels, as well as 
      TrkB mRNA levels, were increased significantly in post-natal day 13 pups after 
      escitalopram treatment as compared to control, but desipramine failed to increase 
      either BDNF or TrkB. The failure of desipramine to increase BDNF and TrkB levels 
      in juvenile rats is consistent with the lack of efficacy of desipramine in 
      children and adolescents. The serotonergic nervous system matures earlier than 
      the noradrenergic system, which may explain why escitalopram, but not 
      desipramine, increases BDNF and TrkB levels.
FAU - Kozisek, Megan E
AU  - Kozisek ME
AD  - Department of Pharmacology and Experimental Neuroscience, University of Nebraska 
      Medical Center, 985800 Nebraska Medical Center, Omaha, NE 68198-5800, USA. 
      megankozisek@yahoo.com
FAU - Middlemas, David
AU  - Middlemas D
FAU - Bylund, David B
AU  - Bylund DB
LA  - eng
GR  - MH064772/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20070810
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Antidepressive Agents, Tricyclic)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (RNA, Messenger)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 0DHU5B8D6V (Citalopram)
RN  - EC 2.7.10.1 (Receptor, trkB)
RN  - TG537D343B (Desipramine)
SB  - IM
MH  - Aging/metabolism
MH  - Animals
MH  - Antidepressive Agents, Tricyclic/pharmacokinetics/*pharmacology
MH  - Brain-Derived Neurotrophic Factor/*biosynthesis
MH  - Chromatography, High Pressure Liquid
MH  - Citalopram/pharmacokinetics/*pharmacology
MH  - Desipramine/pharmacokinetics/*pharmacology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Hippocampus/metabolism
MH  - Injections, Intraperitoneal
MH  - Prefrontal Cortex/metabolism
MH  - RNA, Messenger/biosynthesis/isolation & purification
MH  - Rats
MH  - Receptor, trkB/*biosynthesis
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Selective Serotonin Reuptake Inhibitors/pharmacokinetics/*pharmacology
EDAT- 2007/12/01 09:00
MHDA- 2008/05/13 09:00
CRDT- 2007/12/01 09:00
PHST- 2007/05/31 00:00 [received]
PHST- 2007/07/23 00:00 [revised]
PHST- 2007/08/01 00:00 [accepted]
PHST- 2007/12/01 09:00 [pubmed]
PHST- 2008/05/13 09:00 [medline]
PHST- 2007/12/01 09:00 [entrez]
AID - S0028-3908(07)00246-8 [pii]
AID - 10.1016/j.neuropharm.2007.08.001 [doi]
PST - ppublish
SO  - Neuropharmacology. 2008 Feb;54(2):251-7. doi: 10.1016/j.neuropharm.2007.08.001. 
      Epub 2007 Aug 10.